U.S. markets closed
  • S&P 500

    3,963.51
    +29.59 (+0.75%)
     
  • Dow 30

    33,781.48
    +183.56 (+0.55%)
     
  • Nasdaq

    11,082.00
    +123.45 (+1.13%)
     
  • Russell 2000

    1,818.29
    +11.39 (+0.63%)
     
  • Crude Oil

    71.79
    +0.33 (+0.46%)
     
  • Gold

    1,801.30
    +3.30 (+0.18%)
     
  • Silver

    23.27
    +0.35 (+1.54%)
     
  • EUR/USD

    1.0561
    +0.0047 (+0.44%)
     
  • 10-Yr Bond

    3.4910
    +0.0830 (+2.44%)
     
  • GBP/USD

    1.2235
    +0.0030 (+0.25%)
     
  • USD/JPY

    136.6450
    +0.1210 (+0.09%)
     
  • BTC-USD

    17,210.93
    +355.89 (+2.11%)
     
  • CMC Crypto 200

    405.01
    +10.32 (+2.62%)
     
  • FTSE 100

    7,472.17
    -17.02 (-0.23%)
     
  • Nikkei 225

    27,574.43
    -111.97 (-0.40%)
     

KalVista shares slide 47% premarket after company halts trial of treatment for hereditary angioedema

KalVista shares slide 47% premarket after company halts trial of treatment for hereditary angioedema

KalVista Pharmaceuticals Inc. shares tumbled 47% in premarket trade Tuesday, after the company said it's halting a Phase 2 trial of a treatment for hereditary angioedema, after multiple patients showed liver enzyme elevations. No patients had concomitant elevation of bilirubin levels and all were asymptomatic, the company said in a statement. "We made the difficult decision to terminate KOMPLETE because we concluded that the emerging safety profile of the current formulation will not meet our re